Tylenol Autism/ADHD Lawsuit

What Is the Tylenol Autism/ADHD Lawsuit?

The Tylenol autism/ADHD lawsuit is a mass tort action alleging that prenatal use of acetaminophen — the active ingredient in Tylenol and many store-brand pain relievers — increases the risk of autism spectrum disorder (ASD) and attention deficit hyperactivity disorder (ADHD) in children. Multiple peer-reviewed studies have found a statistical association between acetaminophen exposure during pregnancy and neurodevelopmental disorders.

These cases have been consolidated into MDL 3043 in the Southern District of New York, presided over by Judge Denise Cote. The litigation names Johnson & Johnson (now spun off as Kenvue for consumer health products) as the primary defendant, along with major retailers that sold store-brand acetaminophen products.

Important note: This litigation has faced a significant legal setback. In December 2023, Judge Cote ruled to exclude the plaintiffs' expert testimony on general causation under the Daubert standard. This ruling is currently being appealed. Prospective claimants should understand this challenge and discuss it with an attorney before making decisions about filing. Read more below in the Daubert ruling section.

If you used acetaminophen during pregnancy and your child has been diagnosed with ASD or ADHD, an attorney can evaluate your case in the context of the current legal landscape. Learn about how mass tort lawsuits work for background on the process.

The Daubert Ruling — A Significant Setback

The Daubert standard is the legal framework federal courts use to determine whether scientific expert testimony is admissible at trial. Under Daubert v. Merrell Dow Pharmaceuticals (1993), judges act as "gatekeepers" to ensure that expert testimony is based on reliable scientific methodology.

In her December 2023 ruling, Judge Cote found that the plaintiffs' experts had not sufficiently established that acetaminophen causes autism or ADHD under this standard. While the epidemiological studies show a statistical association between prenatal acetaminophen use and neurodevelopmental disorders, the judge concluded that the experts' methodology for establishing causation — as opposed to correlation — was not sufficiently reliable.

What this means in practice: Without admissible expert testimony on general causation, cases in MDL 3043 cannot proceed to trial. This effectively pauses the litigation until the appeal is resolved.

The appeal: Plaintiffs have appealed the Daubert ruling to the Second Circuit Court of Appeals. If the appellate court overturns or modifies the ruling, cases could proceed. If the ruling is upheld, the MDL will likely be dismissed, though individual state-court cases with different evidentiary standards may continue.

Despite this setback, many legal experts note that Daubert rulings are sometimes overturned on appeal, and new scientific research may strengthen the plaintiffs' position over time. If you believe you have a claim, it is worth consulting an attorney to preserve your rights.

Products Involved

The Tylenol autism/ADHD lawsuit covers acetaminophen in all forms — brand name, store brand, and combination products. Unlike some mass tort cases that target a specific product formulation, this litigation focuses on the active ingredient (acetaminophen) itself and the failure to warn about its potential neurodevelopmental risks during pregnancy.

Who Qualifies for the Tylenol Lawsuit?

Eligibility for the Tylenol autism/ADHD lawsuit requires demonstrating both prenatal acetaminophen use and a subsequent neurodevelopmental diagnosis in the child. Given the Daubert ruling and pending appeal, it is especially important to consult with an attorney who can evaluate your case within the current legal context.

Even with the current legal uncertainty, preserving your rights by filing within the statute of limitations is important. Request a free case evaluation to discuss your situation with an experienced attorney.

Lawsuit Timeline

The Tylenol autism/ADHD litigation has progressed through several critical stages, from initial scientific research through the current Daubert appeal. Understanding this timeline helps set realistic expectations about the case.

Settlement Amounts & Projections

Important context: No settlements have been reached in MDL 3043, and the December 2023 Daubert ruling has created significant uncertainty about the future of this litigation. The settlement ranges shown below are speculative projections by legal analysts, contingent on the Daubert ruling being overturned and the litigation proceeding.

If the appeal is successful and cases proceed, compensation would likely be tiered based on the severity of the child's diagnosis and the degree of care required. These projections should not be interpreted as guarantees or predictions.

For context on how mass tort settlements work generally, see our guide on mass tort settlement amounts.

How to File a Claim

Filing a Tylenol autism/ADHD claim follows the standard mass tort process, though the current status of the litigation adds an important consideration. An attorney experienced in this specific MDL can advise you on timing and strategy. Most work on a contingency fee basis, meaning you pay nothing unless you receive compensation.

Named Defendants

The Tylenol autism/ADHD lawsuits name the manufacturer of the brand-name product as well as major retailers that sold acetaminophen under their store-brand labels:

• Johnson & Johnson / Kenvue — Manufacturer of Tylenol, the most widely recognized acetaminophen brand. In 2023, J&J spun off its consumer health division as Kenvue, which now holds the Tylenol brand. The lawsuits target both entities.
• Retailers — Major retailers that sold store-brand (generic) acetaminophen products are also named as defendants, including CVS Health, Walgreens, Walmart, Target, Rite Aid, Costco, and others. These retailers are accused of selling acetaminophen without adequate pregnancy warnings on their store-brand products.

The inclusion of retailers is notable because store-brand acetaminophen makes up a significant portion of the market. The lawsuit argues that all sellers of acetaminophen — not just J&J — had a duty to warn about potential neurodevelopmental risks. This is similar to the approach taken in the NEC baby formula lawsuit, where multiple manufacturers are held accountable.

Scientific & Medical Evidence

The scientific basis for the Tylenol autism/ADHD lawsuit consists of epidemiological studies showing a statistical association between prenatal acetaminophen exposure and neurodevelopmental disorders. While this body of research was found insufficient to meet the Daubert standard in the December 2023 ruling, the studies themselves remain part of the scientific record:

• A 2014 JAMA Pediatrics study of over 64,000 Danish mothers and children found that prenatal acetaminophen use was associated with a higher risk of ADHD-like behaviors and hyperkinetic disorders.
• A 2016 International Journal of Epidemiology study found that frequent prenatal acetaminophen use was associated with ASD with hyperactivity symptoms in children.
• A 2018 meta-analysis published in the American Journal of Epidemiology reviewed multiple studies and concluded that prenatal acetaminophen exposure was associated with increased risk of both ASD and ADHD.
• A 2021 consensus statement signed by 91 scientists and clinicians called for precautionary action regarding prenatal acetaminophen use, citing the growing body of evidence.

It is important to distinguish between association and causation. The studies above demonstrate a statistical link, but the Daubert ruling reflects the court's determination that the plaintiffs' experts did not sufficiently bridge the gap from correlation to causation under the applicable legal standard. The appeal could change this determination. Additional research may also provide stronger evidence in the future.